SCHEMBL4499269

SCHEMBL4499269

O=C(O)c1cc(-c2ccccc2)oc1-c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.72
ALDH1A1 P00352 6/20 0.60
KDM4E B2RXH2 2/20 0.60
POLB P06746 2/20 0.54
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KLKB1 P03952 1/20 0.47
CDC7 O00311 1/20 0.47
HPGD P15428 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PKM P14618 1/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NR4A2 P43354 1/20 0.43
PTPRC P08575 1/20 0.43
PTPN9 P43378 1/20 0.43
PTPN11 Q06124 1/20 0.43
PTPN22 Q9Y2R2 1/20 0.43
HNF4A P41235 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11462813 0.85 PDE4A (0.68) PDE4AALDH1A1KDM4EPOLBNPC1
SCHEMBL7735082 0.84 PDE4A (0.53) PDE4AALDH1A1KDM4ENPC1RAB9A
SCHEMBL17999250 0.81 PDE4A (0.62) PDE4AALDH1A1KDM4EPOLBCDC7
SCHEMBL11661869 0.81 ALDH1A1 (0.60) PDE4AALDH1A1KDM4ENPC1RAB9A
SCHEMBL3973961 0.79 KDM4E (0.62) PDE4AALDH1A1KDM4ENPC1RAB9A
SCHEMBL557753 0.79 NPC1 (0.73) PDE4AALDH1A1KDM4ENPC1RAB9A
SCHEMBL29858672 0.77 ALDH1A1 (0.59) PDE4AALDH1A1KDM4ERAB9AHPGD
Acetic Acid SCHEMBL28745643 0.77 NPC1 (0.69) PDE4AALDH1A1KDM4ENPC1RAB9A
SCHEMBL9822648 0.77 PDE4A (0.53) PDE4AALDH1A1KDM4EPOLBNPC1
SCHEMBL595184 0.75 ALDH1A1 (0.54) PDE4AALDH1A1KDM4EPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917262-B1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-12-14 EP disclosed
US-7491821-B2 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders ROCHE PALO ALTO LLC (US) 2009-02-17 US disclosed
EP-1917262-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP disclosed
WO-2007020194-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 PDE4A 693/4885ALDH1A1 2159/4885KDM4E 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.